Anges Inc News Today

The artificial blood vessels market is anticipated to grow significantly in the coming years, driven by advancements in biotechnology and the rising prevalence of cardiovascular diseases. With

The artificial blood vessels market is anticipated to grow significantly in the coming years, driven by advancements in biotechnology and the rising prevalence...

May 29, 2024 Company Name: AnGes Inc. Presentative: Ei Yamada, President & CEO Tie2 receptor agonist ,co-development...

The surge in demand for angioplasty balloons and stents is mainly driven by the increasing prevalence of cardiovascular diseases (CVDs), the growing preference...

CAMBRIDGE, United Kingdom and NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led b...

/PRNewswire/ -- DelveInsights Drug-Eluting Balloons Market Insights report provides the current and forecast market analysis, individual leading drug-eluting...

Clinical trial data demonstrated Zokinvy treatment extended life by an average of 4.3 years in children and young adults with Hutchinson-Gilford progeriaEiger to receive $500,000 approval milestone...

Eiger BioPharmaceuticals, Inc. announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy , a treatment for...

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

Dublin, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The